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 Introduction 
 With objectives of enhanced efficiency, cost control, and 
improved quality of clinical research, the newly formed Clinical 
and Translational Science Award (CTSA) Consortium sought 
to identify and remedy obstacles within the clinical research 
management process as a top priority at its fi rst meeting in 2006. 
A commitment to clinical research is a core value for nearly all 
of the CTSA applicants and, therefore, maintenance of optimal 
performance standards for clinical research is of central concern. 
Clinical research is also a major priority for the public and private 
sectors, as evidenced by its strong support by the National 
Institutes of Health (NIH), industry, and a broad spectrum of 
health care advocacy groups. 
 According to workshop presenter Robert Califf , M.D. (Duke 
University), a lynchpin of healthcare reform is considered to be 
the development and objective assessment of new diagnostics, 
drugs, devices, and behavioral interventions, because these will 
provide a rational basis for choice when evaluating health care 
options. However, the development and assessment of products 
and interventions depends entirely on a fi rm platform for the 
performance of clinical research, much of which is conducted 
at Academic Medical Centers (AMCs), and critical to the 
achievement of these goals is the development of objectively 
verifi able methods to measure the improvement of research 
management and conduct. 
 In February 2010, www.ClinicalTrials.gov listed 13,000 open, 
interventional clinical trials in the United States. However, there is 
widespread concern that the trials are being conducted with less than 
maximal effi  ciency, thus implying a need for improvement in clinical 
research management at AMCs. Many AMCs have developed robust 
clinical research programs, which operate largely in isolation from 
each other with little opportunity for sharing lessons learned and 
best practices for conducting clinical research. 
 Among its many other functions, the CTSA Consortium 
provides a setting where clinical research management 
counterparts at CTSA-associated AMCs can exchange ideas 
and strategies to improve the processes that support clinical 
research. Th e 2nd Annual CTSA Clinical Research Management 
Workshop provided a face-to-face venue whereby representatives 
from industry, research, NIH and Food and Drug Administration 
(FDA) could gather to exchange initiatives and methodologies 
(http://www.ctsaweb.org/index.cfm?fuseaction=meeting.view
Meeting&year=2009&com_ID=221#mtg_ID_1160). 
 Delays in initiation of clinical research 
 Th e conduct of clinical research is challenged by the complexity 
of the regulatory environment, limited funding opportunities, 
institutional ineffi  ciencies, and inadequate patient recruitment, 
enrollment, and retention. Attendees at the workshop learned 
of instruments used in the private sector to assess the effi  ciency 
of clinical trials activation, enrollment, and completion. Tracy 
Blumenfeld (RapidTrials; Tuft s) reported that between 2002 
and 2007, for selected industry sponsored trials, the time from 
protocol approval, by the regulatory sponsor, to the date of the 
fi rst visit of the fi rst subject had increased by 74%. Moreover, 
under-enrollment was severe. Up to 25% of clinical trials Rapid 
Trials reported failed to enroll a single patient even aft er spending 
many hours and dollars activating them. Almost half of research 
sites report that studies are delayed by intermediaries; since 
2006, administrative procedures and protocol amendments 
have increased by 12% and 50%, respectively (RapidTrials). 
According to data gathered by the Tuft s Center for the Study 
of Drug Development, over 90% of all clinical trials fail to meet 
expected completion dates because of overly optimistic timelines 
and inadequate patient enrollment (Califf  ). Patient advocacy 
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 Abstract 
 The Clinical and Translational Science Award (CTSA) Consortium Workshop was conceived as a venue to foster communication among 
Academic Medical Centers (AMCs) in the development of methods to improve clinical research management. The consortium, com-
prised of 46 awardee sites as of 2009, many with multiple AMCs, is expected to expand to 60 sites when fully implemented. At the 
2nd Annual CTSA Clinical Research Management Workshop held on June 22 nd and 23 rd , 2009, on the National Institutes of Health 
(NIH) campus, consortium members and potential CTSA sites gathered with stakeholders from private industry, the NIH, the Food and 
Drug Administration, and private research organizations, to formulate a plan to address challenges in clinical research management. 
Specifi c aims included improving protocol processing and sharing process improvement initiatives in the expectation that best practices 
will be implemented and improvements will be measured and reported. The fi ndings presented at this workshop indicated signifi cant 
variance in Institutional Review Board approval of protocols and contract execution by AMC and CTSA sites. Most represented marked 
delays compared to non-AMC sites and that, as a likely consequence, AMCs were later to enroll patients and/or meet enrollment targets 
compared to dedicated or professional sites . Clin Trans Sci 2010; Volume 3: 305–308
 Keywords: clinical research, follow-up studies
306 VOLUME 3 • ISSUE 6 WWW.CTSJOURNAL.COM
Johnson et al.   Using Research Metrics to Improve Timelines 
groups consistently identify delay times as adverse to the interests 
of patients (Califf ). Even aft er activation, an estimated 20% of 
clinical trials fail to enroll a single patient and an additional 30% 
under-enroll (Califf ; Tuft s). Clinical research is increasingly being 
conducted abroad: one-third of phase III trials conducted by the 
20 largest U.S. pharmaceutical companies are being conducted 
solely outside the United States (NEJM; 2009 Feb 19;360(8):816–
823). Since 2002, the number of FDA investigators outside the 
United States has grown by 15% annually, whereas the number 
in the United States has declined by 5.5%. 
 Using metrics to drive clinical site performance improvement 
 The use of metrics to evaluate the management of clinical 
research process is a logical approach to understanding why and 
where delays occur and as a tool for measuring baseline and 
improvement. Pharmaceutical companies have shift ed toward 
this approach as a basis for site selection, with a trend toward 
eliminating poor or non-performing sites (RapidTrials). Th e 
shift  toward performance characteristics was further accentuated 
during the recent economic downturn which sharpened concerns 
about maximizing the value of investments in clinical research. 
At the 2009 CTSA Clinical Research Management Workshop, 
private industry and members of the CTSA Consortium presented 
clinical research process data to develop methods for improving 
research timelines on both an institutional and collective level. 
Leaders of the CTSA Consortium have proposed the application 
of a standardized set of metrics for clinical research management 
across multiple academic sites, allowing for comparisons and the 
identifi cation of best practices. Standardized metrics have the 
potential of establishing benchmark performance and reducing 
variability between AMCs at CTSA sites. If successful, standardized 
metrics could be expanded to clinical research centers outside of 
the CTSA sites as well. 
 In the private sector, Briggs Morrison from Pfi zer surveyed 
the company’s clinical trials conducted between 2006 and 2009; 
he compared CTSA-associated AMCs with other AMCs and non-
AMCs and showed that each of these institutions had similar 
patient enrollment rates but that about 30% of activated sites did 
not enroll any patients and about half enrolled no more than three 
patients. Th e duration between protocol approval and initiation 
of patient screening was less at non-AMC sites (median 210 days) 
than at CTSA or other AMC sites (median 265.5 and 257 days, 
respectively). Th e duration between protocol approval by Pfi zer 
and the receipt of a signed contract was longer at CTSA and AMC 
sites than at non-AMC sites: for non-AMCs the median was 
42 days, while the median for CTSA and AMC sites was 165 and 
141 days. Once patient enrollment was initiated, the time from 
fi rst screened patient to last screened patient was comparable 
across the three types of institutions (Pfi zer). Th us, the Morrison 
analysis indicated that contracting times were prolonged at AMCs 
(including CTSA sites) when compared to non-AMC sites, which 
was also identifi ed by the CTSA Consortium as a concern. Indeed, 
the CTSA Consortium had launched pilot studies to identify 
potentially correctable causes of prolongation of contracting times 
at CTSA-related AMCs. 
 In one of the largest cross-company, independently collected 
data sets analyzed to date, RapidTrials examined research metrics 
at AMCs, dedicated research centers, and professional sites with 
which it contracted on behalf of pharmaceutical companies for 
clinical research. Th e survey, which included data collected from 
1997 to 2008 from 5 of the top 10 pharmaceutical companies, 
examined studies involving 7,049 principal investigators, 
14,857 sites and 91,783 subjects in trials on 121 compounds in 
10 therapeutic areas. Th e data showed that study initiation at 
academic centers takes 49 days longer than at professional and 
community sites, placing academic centers at an enrollment 
disadvantage. Once studies are initiated, AMCs are approximately 
10% slower to enroll than dedicated and professional sites, and 
although AMCs are better at screening for appropriate study 
participants, more participants remain on study until completion 
at non-AMC sites than at CTSA and other AMC sites. 
 CTSA Pilot Studies to Identify Study Initiation Bottlenecks 
 IRB metrics 
 At the 1st Annual CTSA Clinical Research Management Workshop 
(2008), the consortium reached a consensus to use research metrics 
to evaluate time to study initiation and began by conducting a 
pilot study on Institutional Review Board (IRB) metrics as a fi rst 
step. A pilot protocol for the study of protocol processing by IRBs 
at individual CTSA-associated AMCs was designed to gather 
the data necessary to provide a better understanding of trends 
and review processes and to establish baseline data to promote 
the understanding of review characteristics common at all 
participating CTSA sites (http://www.ctsaweb.org/uploadedfi les/
Final_CTSA_IRB1.pdf). Th e purpose of the study was to identify 
common practices that exist at all AMCs, regardless of process, 
to be used in future research so as to further identify, implement, 
monitor, and standardize protocol process improvements across 
the CTSA Consortium. The objectives were to collect data 
pertaining to the complete review of up to 25 comprehensive 
clinical protocols by fully convened IRB(s) at each CTSA site; to 
determine the median times for completion of approvals (75%, 
90%, and 100%) for protocols approved in the month of February 
2009. Th e intent was to develop an understanding of the process 
based on data analysis which, in turn, could be used to defi ne 
relevant metrics that could serve as tools to improve and monitor 
the management of clinical trial protocol approvals. A total of 200 
protocols were targeted, but that number was exceeded when 31 
of the 38 CTSA sites reported on 378 protocols. 
 A preliminary review of the data showed no variance by 
year of award or by volume of protocols in 2008. However, the 
results showed that there is wide variability among institutions 
on defi nitions and steps in the IRB review and approval process. 
Many CTSA sites review some studies through external IRBs 
and other studies through internal IRBs; some sites include 
comprehensive scientifi c review in the IRB process and others 
do not. Ancillary data showed that 18 sites (out of 28 submitting 
data on this topic) have a system for electronic submission of at 
least half of all protocols, with 11 sites utilizing full electronic 
submission for all protocols. Th e mean number of IRB support 
staff  per site was 15.4 (29 sites reporting), the majority of sites 
(25 out of 28) had fi ve or fewer biomedical IRBs, and 21 sites 
reported using an external IRB. 
 Th is study, with more than 75% of CTSA sites participating, in 
a collaborative process, identifi ed the variances in the IRB process 
across sites and the challenges associated with developing an IRB 
metrics repository of comparative data to facilitate IRB process 
improvements (CTSA Regulatory and Ethics IRB Taskforce). 
During the past year, many CTSA sites have examined, evaluated 
and modifi ed their approval processes and have taken steps to 
reduce study initiation timelines. Workshop participants had 
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the opportunity to view this progress at a poster session, during 
which they exchanged information with colleagues. 
 Contract execution metrics 
 In addition to the study on IRB metrics, a pilot study was 
initiated to determine whether the CTSA could study the 
contract execution processes to develop objective metrics to 
be used for process improvement (http://www.ctsaweb.org/
uploadedfi les/Contracts_CTSAContractsTaskfor14.pdf). Th e 
objectives included the collection of defi ned time data points at 
all CTSA sites, the determination of median completion times 
for execution of contracts, and the collection of information on 
factors that may infl uence contract negotiation times. Th is study 
is especially relevant in light of the data presented by Pfi zer in 
which delays in executing contracts were a major factor in study 
initiation delays. Th e study, which focuses on industry-initiated, 
industry-sponsored clinical trials, began on April 1, 2009 and 
was scheduled to end when all participating sites had recorded 
the execution date of 90% of the contracts that site was tracking 
in the study. At the time of the presentation, 30 CTSA sites had 
submitted data on 498 contracts. When complete, the information 
obtained from the study will be used to develop future studies 
to provide evidence to support eff orts to improve timelines for 
contracts negotiation, to examine processes with a view towards 
improvement, to develop methods of data collection, to identify 
obstacles to collecting data, and to inform the design of future 
studies. 
 Conclusion 
 Th e operations associated with the management and conduct 
of clinical research resemble other enterprises that combine 
human eff ort and technology to produce a product and should 
have similar goals of standardization, systems development and 
measurement to produce a better product (Califf ). Th e CTSA is 
well positioned to oversee the collection, analysis and application 
of research metrics that will help its AMCs move toward this 
goal and has taken steps to set the process in motion. In addition 
to presentations and discussions of pilot data from CTSA sites, 
several themes emerged from the workshop that will set the 
stage for improvements in the quality and effi  ciency of clinical 
research. 
 Th e consortium’s clinical research management improvement 
plan includes continued pursuit of data-driven, transparent 
approaches to process improvement. Th is includes mapping and 
analysis of prestudy processing and assessment of performance 
times as a function of study characteristics such as number of 
sites, type of population, previous experience of investigator, 
investigational agent (under the Investigational New Drug 
program), or sponsor. Transparent reporting, such as might be 
accomplished by posting metrics on a website, would demonstrate 
responsibility and accountability; these factors would improve the 
research process for investigators, sponsors, research teams, and 
patients. Although participants at the workshop contemplated 
more aggressive goals, such as a maximum number of days from 
fi nal protocol approval, by the sponsor, to fi rst patient fi rst visit, 
they reached a consensus: individual institutions might best begin 
by evaluating their internal processes and eliminating steps that 
do not add value. Sites might also benefi t from standardization 
of contracting terms or the development of a standard menu that 
could be adapted to eliminate or reduce contract negotiation 
delays. Beyond examining ways in which clinical trials could 
be conducted more effi  ciently, the consortium intends to tackle 
additional measures of performance such as issues related to 
quality, trial completion (e.g., recruitment and retention), and 
costs. To this end, the CTSA Regulatory and Knowledge Support 
Key Function Committee convened a Recruitment/Retention 
Taskforce, which has begun to examine practices across the 
consortium. 
 Th e sharing of best practices, the development of consortium 
standards and the review of data on an annual basis will all play 
an important role in future Clinical Research Management 
Workshops. Th e 2009 workshop revealed a collaborative and 
cooperative environment between CTSA Consortium members, 
boding well for future gatherings. In the meantime, eff ective 
teamwork across and among institutions, motivated leadership, 
a supportive culture, and above all, a willingness to examine and 
change systems and processes that are in place will all contribute 
to substantial improvement in clinical research management . 
 Glossary of Terms 
 AMC: Academic Medical Center. 
 Clinical research: Research conducted with human subjects (or 
on material of human origin such as tissues, specimens, and 
cognitive phenomena) for which an investigator (or colleague) 
directly interacts with human subjects; excluded from this 
defi nition are  in vitro studies that utilize human tissues that 
cannot be linked to a living individual. Patient-oriented 
research includes: mechanisms of human disease, therapeutic 
interventions, clinical trials, development of new technologies, 
epidemiological and behavioral studies, or outcomes and health 
services research. 
 CRO: Contract Research Organization, also called a Clinical 
Research Organization, (CRO), a service organization that 
provides support to the pharmaceutical and biotechnology 
industries. CROs off er clients a wide range of “outsourced” 
pharmaceutical research services. 
 CTSA Consortium: A national consortium of medical research 
institutions, funded through CTSA, working together to improve 
the way biomedical research is conducted nationwide. Consortium 
members share a common vision to reduce the time it takes for 
laboratory discoveries to become treatments for patients, to engage 
communities in clinical research eff orts and to train clinical and 
translational researchers. 
 CTSA Regulatory and Ethics IRB Taskforce: A consortium 
subgroup formed to create a document that embodies suggestions 
for improvements to the process of IRB oversight of multicenter 
studies. 
 FDA: Food and Drug Administration. 
 IND: Investigational New Drug program is the means by 
which a pharmaceutical company obtains permission to ship 
an experimental drug across state lines (usually to clinical 
investigators) before a marketing application for the drug has 
been approved. Interventional Clinical Trial: Studies in human 
beings in which individuals are assigned by an investigator based 
on a protocol to receive specifi c interventions. Subjects may 
receive diagnostic, therapeutic, or other types of interventions. 
Th e assignment of the intervention may or may not be random. 
Th e individuals are then followed and biomedical and/or health 
outcomes are assessed. 
 IRB: Institutional Review Board; an organizational committee 
that reviews and approves biomedical research that uses humans 
as subjects. 
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 Key Function Communities/Committees (KFCs): Consortium-
wide forums for communication and sharing best practices across 
areas of clinical and translational research. 
 KFC Task Force: Implementation groups developed from 
volunteer members drawn from the KFCs to initiate and carry 
out specifi ed consortium projects such as developing resource 
networks, completing white papers, and others; groups will sunset 
on project completion 
 NIH: National Institutes of Health 
 Phase III Trial: Clinical trial to evaluate a drug or treatment that 
has proven eff ective in the phase I and II trials and is tested on a 
large population (1,000–3,000) to confi rm its eff ectiveness, reveal 
any rarer side eff ects, and gather information that will allow the 
drug or treatment to be safely marketed. 
 PI: Principal investigator; the individual responsible for the 
conduct of the study at each participating institution. 
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 RapidTrials: A Contract Research Organization (CRO) formed 
to help sites optimize performance on clinical trials. 
 Translational Research: Transforms scientifi c discoveries arising 
from laboratory, clinical, or population studies into clinical 
applications to reduce morbidity and mortality and improve 
population health. 
